01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

Dosing and administration for M-M-R®II

Actor Portrayal

Vaccine schedule for M-M-R®II

M-M-R®II offers health care providers like you a dosing regimen to help protect infants and children against measles, mumps, and rubella.

1st dosea

12–15 months of age

2nd doseb

4–6 years of age

aChildren who received an initial dose of MMR vaccine prior to their first birthday should receive additional doses of vaccine at 12–15 months of age and at 4–6 years of age to complete the vaccination series.

bSecond dose may be administered prior to 4 years of age, provided that there is a minimum interval of one month between the doses of MMR vaccine, live.

Flexible route of administration for M-M-R®II

M-M-R®II has helped to protect patients for over 40 years. As of 2023, it can be administered either subcutaneously or intramuscularly.

A single dose of M-M-R®II is approximately 0.5 mL. It is administered intramuscularly or subcutaneously into the outer part of the upper arm or into the anterolateral area of the thigh.

M-M-R®II: Part of the MMRV Family

Discover the MMRV Family

Actual size not shown

Looking to stock M-M-R®II in your practice?

Simply register or log in to your account to get started.

Order M-M-R®II today

Reconstitution

Learn how to reconstitute M-M-R®II using a prefilled diluent syringe.

View MMR reconstitution video

Storage and handling

Find out about the flexible storage options and handling of M-M-R®II

Review MMR storage options

Indications and Usage for M-M-R®II

  • M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II

  • M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.
  • The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and Administration

  • FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

 

Indications and Usage for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.
  • The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and Administration

  • FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

 

M-M-R®II is contraindicated in certain individuals, including those with: a history of

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those